MeiraGTx Holdings plc Net Income (Loss) Available to Common Stockholders, Basic
MeiraGTx Holdings plc (MGTX) reported Net Income (Loss) Available to Common Stockholders, Basic of $160.72 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-13
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was $160.72M.
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$46.31M.
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was $15.09M.
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$50.51M.
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for fiscal 2025 was -$114.20M.
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for fiscal 2024 was -$147.79M.
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for fiscal 2023 was -$84.03M.
- MeiraGTx Holdings plc net income (loss) available to common stockholders, basic for fiscal 2022 was -$129.62M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $160.72M 10-Q · filed 2026-08-13 | $114.41M 10-Q · filed 2026-08-13 | $129.50M derived: sum of 3 quarters · filed 2026-08-13 | $78.98M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | -$46.31M 10-Q · filed 2026-05-14 | -$31.23M derived: sum of 2 quarters · filed 2026-05-14 | -$81.74M derived: sum of 3 quarters · filed 2026-05-14 | -$120.53M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $15.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$35.42M derived: sum of 2 quarters · filed 2026-03-30 | -$74.22M derived: sum of 3 quarters · filed 2026-08-13 | -$114.20M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | -$50.51M 10-Q · filed 2025-11-13 | -$89.31M derived: sum of 2 quarters · filed 2026-08-13 | -$129.29M 10-Q · filed 2025-11-13 | -$168.69M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$38.80M 10-Q · filed 2026-08-13 | -$78.78M 10-Q · filed 2026-08-13 | -$118.17M derived: sum of 3 quarters · filed 2026-08-13 | -$157.50M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$39.98M 10-Q · filed 2026-05-14 | -$79.38M derived: sum of 2 quarters · filed 2026-05-14 | -$118.71M derived: sum of 3 quarters · filed 2026-05-14 | -$167.33M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$39.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$78.73M derived: sum of 2 quarters · filed 2026-03-30 | -$127.35M derived: sum of 3 quarters · filed 2026-03-30 | -$147.79M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | -$39.33M 10-Q · filed 2025-11-13 | -$87.95M derived: sum of 2 quarters · filed 2025-11-13 | -$108.39M 10-Q · filed 2025-11-13 | -$88.18M derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$48.62M 10-Q · filed 2025-08-14 | -$69.06M 10-Q · filed 2025-08-14 | -$48.85M derived: sum of 3 quarters · filed 2025-08-14 | -$93.14M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$20.44M 10-Q · filed 2025-05-13 | -$227.00K derived: sum of 2 quarters · filed 2025-05-13 | -$44.52M derived: sum of 3 quarters · filed 2025-05-13 | -$74.11M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $20.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | -$24.08M derived: sum of 2 quarters · filed 2025-03-13 | -$53.66M derived: sum of 3 quarters · filed 2025-03-13 | -$84.03M 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | -$44.30M 10-Q · filed 2024-11-13 | -$73.88M derived: sum of 2 quarters · filed 2024-11-13 | -$104.24M 10-Q · filed 2024-11-13 | -$131.56M derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$29.58M 10-Q · filed 2024-08-12 | -$59.95M 10-Q · filed 2024-08-12 | -$87.26M derived: sum of 3 quarters · filed 2024-08-12 | -$124.54M derived: sum of 4 quarters · filed 2024-08-12 | ||||
| 2023-03-31 | -$30.36M 10-Q · filed 2024-05-09 | -$57.68M derived: sum of 2 quarters · filed 2024-05-09 | -$94.96M derived: sum of 3 quarters · filed 2024-05-09 | -$128.93M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$27.31M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$64.60M derived: sum of 2 quarters · filed 2024-03-15 | -$98.57M derived: sum of 3 quarters · filed 2024-03-15 | -$129.62M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | -$37.28M 10-Q · filed 2023-11-14 | -$71.26M derived: sum of 2 quarters · filed 2023-11-14 | -$102.30M 10-Q · filed 2023-11-14 | -$112.21M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$33.97M 10-Q · filed 2023-08-10 | -$65.02M 10-Q · filed 2023-08-10 | -$74.93M derived: sum of 3 quarters · filed 2023-08-10 | -$100.88M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$31.05M 10-Q · filed 2023-05-11 | -$40.96M derived: sum of 2 quarters · filed 2023-05-11 | -$66.90M derived: sum of 3 quarters · filed 2023-05-11 | -$86.99M derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | -$9.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$35.86M derived: sum of 2 quarters · filed 2023-03-14 | -$55.94M derived: sum of 3 quarters · filed 2023-03-14 | -$79.56M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | -$25.95M 10-Q · filed 2022-11-10 | -$46.03M derived: sum of 2 quarters · filed 2022-11-10 | -$69.65M 10-Q · filed 2022-11-10 | -$80.11M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$20.09M 10-Q · filed 2022-08-11 | -$43.70M 10-Q · filed 2022-08-11 | -$54.16M derived: sum of 3 quarters · filed 2022-08-11 | -$60.60M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$23.62M 10-Q · filed 2022-05-12 | -$34.08M derived: sum of 2 quarters · filed 2022-05-12 | -$40.51M derived: sum of 3 quarters · filed 2022-05-12 | -$65.93M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$10.46M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | -$16.89M derived: sum of 2 quarters · filed 2022-03-10 | -$42.31M derived: sum of 3 quarters · filed 2022-03-10 | -$57.99M 10-K · filed 2022-03-10 | -$57.99M 10-K · filed 2021-03-11 | |||
| 2020-09-30 | -$6.43M 10-Q · filed 2021-11-10 | -$6.43M 10-Q · filed 2020-11-05 | -$31.85M derived: sum of 2 quarters · filed 2021-11-10 | -$47.53M 10-Q · filed 2021-11-10 | -$47.53M 10-Q · filed 2020-11-05 | -$53.01M derived: sum of 4 quarters · filed 2021-11-10 | ||
| 2020-06-30 | -$25.42M 10-Q · filed 2021-08-11 | -$25.42M 10-Q · filed 2020-08-06 | -$41.10M 10-Q · filed 2021-08-11 | -$41.10M 10-Q · filed 2020-08-06 | -$46.58M derived: sum of 3 quarters · filed 2021-08-11 | -$57.04M derived: sum of 4 quarters · filed 2021-08-11 | ||
| 2020-03-31 | -$15.68M 10-Q · filed 2021-05-11 | -$21.16M derived: sum of 2 quarters · filed 2021-05-11 | -$31.62M derived: sum of 3 quarters · filed 2021-05-11 | -$52.45M derived: sum of 4 quarters · filed 2021-05-11 | ||||
| 2019-12-31 | -$5.48M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | -$15.94M derived: sum of 2 quarters · filed 2021-03-11 | -$36.76M derived: sum of 3 quarters · filed 2021-03-11 | -$54.75M 10-K · filed 2021-03-11 | ||||
| 2019-09-30 | -$10.46M 10-Q · filed 2020-11-05 | -$31.28M derived: sum of 2 quarters · filed 2020-11-05 | -$49.27M 10-Q · filed 2020-11-05 | -$70.32M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | -$20.82M 10-Q · filed 2020-08-06 | -$38.80M 10-Q · filed 2020-08-06 | -$59.86M derived: sum of 3 quarters · filed 2020-08-06 | -$75.29M derived: sum of 4 quarters · filed 2020-08-06 | ||||
| 2019-03-31 | -$17.98M 10-Q · filed 2019-05-14 | -$39.04M derived: sum of 2 quarters · filed 2020-03-11 | -$54.46M derived: sum of 3 quarters · filed 2020-03-11 | -$85.59M derived: sum of 4 quarters · filed 2020-03-11 | ||||
| 2018-12-31 | -$21.06M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | -$36.48M derived: sum of 2 quarters · filed 2020-03-11 | -$67.60M derived: sum of 3 quarters · filed 2020-03-11 | -$84.67M 10-K · filed 2020-03-11 | ||||
| 2018-09-30 | -$15.42M 10-Q · filed 2019-11-07 | -$46.55M derived: sum of 2 quarters · filed 2019-11-07 | -$63.62M 10-Q · filed 2019-11-07 | -$72.78M derived: sum of 4 quarters · filed 2019-11-07 | ||||
| 2018-06-30 | -$31.12M 10-Q · filed 2019-08-07 | -$48.19M 10-Q · filed 2019-08-07 | -$57.36M derived: sum of 3 quarters · filed 2019-08-07 | -$65.99M derived: sum of 4 quarters · filed 2019-08-07 | ||||
| 2018-03-31 | -$17.07M 10-Q · filed 2019-05-14 | -$26.23M derived: sum of 2 quarters · filed 2019-05-14 | -$34.87M derived: sum of 3 quarters · filed 2019-05-14 | -$42.08M derived: sum of 4 quarters · filed 2019-05-14 | ||||
| 2017-12-31 | -$9.17M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | -$17.80M derived: sum of 2 quarters · filed 2019-03-26 | -$25.01M derived: sum of 3 quarters · filed 2019-03-26 | -$31.85M 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | -$8.63M 10-Q · filed 2018-11-08 | -$15.84M derived: sum of 2 quarters · filed 2018-11-08 | -$22.69M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$7.21M 10-Q · filed 2018-08-08 | -$14.05M 10-Q · filed 2018-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |